Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition

Aromatase inhibitor shows efficacy for hormone receptor positive postmenopausal breast cancer. We evaluated the activity of 24 weeks of aromatase inhibition with exemestane for primary breast cancer in a neoadjuvant setting. Patients with stage II/IIIA invasive breast cancer with estrogen receptor (...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer science 2011-04, Vol.102 (4), p.858-865
Hauptverfasser:	Toi, Masakazu, Saji, Shigehira, Masuda, Norikazu, Kuroi, Katsumasa, Sato, Nobuaki, Takei, Hiroyuki, Yamamoto, Yutaka, Ohno, Shinji, Yamashita, Hiroko, Hisamatsu, Kazufumi, Aogi, Kenjiro, Iwata, Hiroji, Takada, Masahiro, Ueno, Takayuki, Saji, Shigetoyo, Chanplakorn, Niramol, Suzuki, Takashi, Sasano, Hironobu
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Androstadienes - therapeutic use Aromatase Aromatase - chemistry Aromatase Inhibitors - therapeutic use Biological and medical sciences Biomarkers, Tumor - analysis Biomarkers, Tumor - metabolism Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Estrogen receptors Female Gynecology. Andrology. Obstetrics Hormones Humans Invasiveness Ki-67 Antigen - metabolism Lymphatic Metastasis Mammary gland diseases Mastectomy, Segmental Medical sciences Middle Aged Neoplasm Staging Post-menopause Postmenopause Progesterone receptors Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Statistics Surgery Survival Rate Toxicity Treatment Outcome Tumors
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!